FGF23 and chronic kidney disease: Thus, sKL treatment was found to prevent FGF-23-induced cardiac hypertrophy (Han et al., 2020; Suassuna et al., 2020) and dysfunction (Navarro-García et al., 2020) in experimental CKD models.